Gabriel S. Salzman

Gabriel S. Salzman

Auto-generated profile, based on publicly available information

Gabriel S. Salzman

Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Protein Science
Verified
Journal Article
Open access
PDF file
FSFern Sha
Fern Sha
GSGabriel Salzman
Gabriel Salzman
AGAnkit Gupta
Ankit Gupta
SKShohei Koide
Shohei Koide
Synthetic binding proteins are constructed using nonantibody molecular scaffolds. Over the last two decades, in‐depth structural and functional analyses of synthetic binding proteins have improved combinatorial library designs and selection strategies, which have resulted in potent platforms that consistently generate binding proteins to diverse targets with affinity and specificity that rival those of antibodies. Favorable attributes of synthetic binding proteins, such as small size, freedom from disulfide bond formation and ease of making fusion proteins, have enabled their unique applications in protein science, cell biology and beyond. Here, we review recent studies that illustrate how synthetic binding proteins are powerful probes that can directly link structure and function, often leading to new mechanistic insights. We propose that synthetic proteins will become powerful standard tools in diverse areas of protein science, biotechnology and medicine.

1 September 2016 in Neuron
Verified
Journal Article
Closed access
GSGabriel S. Salzman
Gabriel S. Salzman
SASarah D. Ackerman
Sarah D. Ackerman
CDChen Ding
Chen Ding
AKAkiko Koide
Akiko Koide
KLKatherine Leon
Katherine Leon
DADemet Araç
Demet Araç

5 September 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GSGabriel S. Salzman
Gabriel S. Salzman
SZShu Zhang
Shu Zhang
AGAnkit Gupta
Ankit Gupta
AKAkiko Koide
Akiko Koide
SKShohei Koide
Shohei Koide
DADemet Araç
Demet Araç
Adhesion G protein-coupled receptors (aGPCRs) play critical roles in diverse biological processes, including neurodevelopment and cancer progression. aGPCRs are characterized by large and diverse extracellular regions (ECRs) that are autoproteolytically cleaved from their membrane-embedded signaling domains. Although ECRs regulate receptor function, it is not clear whether ECRs play a direct regulatory role in G-protein signaling or simply serve as a protective cap for the activating “Stachel” sequence. Here, we present a mechanistic analysis of ECR-mediated regulation of GPR56/ADGRG1, an aGPCR with two domains [pentraxin and laminin/neurexin/sex hormonebinding globulin-like (PLL) and G protein-coupled receptor autoproteolysis-inducing (GAIN)] in its ECR. We generated a panel of high-affinity monobodies directed to each of these domains, from which we identified activators and inhibitors of GPR56-mediated signaling. Surprisingly, these synthetic ligands modulated signaling of a GPR56 mutant defective in autoproteolysis and hence, in Stachel peptide exposure. These results provide compelling support for a ligand-induced and ECR-mediated mechanism that regulates aGPCR signaling in a transient and reversible manner, which occurs in addition to the Stachel-mediated activation. Significance G protein-coupled receptors enable cells to sense extracellular signals and translate them into physiological responses. In addition to a transmembrane domain that transduces signals into the cytoplasm, adhesion G protein-coupled receptors (aGPCRs) have large extracellular regions (ECRs) that interact with proteins in the extracellular space. The goal of this study is to elucidate how ECRs control aGPCR activation. We engineered synthetic binding proteins, termed monobodies, that bind specific domains in the ECR and showed that monobodies can activate or inhibit G-protein signaling. Our data conclusively establish the feasibility of controlling aGPCR signaling using ECR-targeted drug-like molecules and support a model in which ligand binding to the ECR can affect the transmembrane domain and modulate signal transduction.

25 January 2018 in IUCrJ
Verified
Journal Article
Open access
PDF file
PSPavol Skubák
Pavol Skubák
DADemet Araç
Demet Araç
MBMatthew W. Bowler
Matthew W. Bowler
ACAna Correia
Ana Correia
AHAndre Hoelz
Andre Hoelz
NPNavraj S. Pannu
Navraj S. Pannu
Determining macromolecular structures from X-ray data with resolution worse than 3 Å remains a challenge. Even if a related starting model is available, its incompleteness or its bias together with a low observation-to-parameter ratio can render the process unsuccessful or very time-consuming. Yet, many biologically important macromolecules, especially large macromolecular assemblies, membrane proteins and receptors, tend to provide crystals that diffract to low resolution. A new algorithm to tackle this problem is presented that uses a multivariate function to simultaneously exploit information from both an initial partial model and low-resolution single-wavelength anomalous diffraction data. The new approach has been used for six challenging structure determinations, including the crystal structures of membrane proteins and macromolecular complexes that have evaded experts using other methods, and large structures from a 3.0 Å resolution F1-ATPase data set and a 4.5 Å resolution SecYEG–SecA complex data set. All of the models were automatically built by the method toRfreevalues of between 28.9 and 39.9% and were free from the initial model bias.

1 May 2018 in iScience
Verified
Journal Article
Open access
ONOlha Nazarko
Olha Nazarko
AKAmanuel Kibrom
Amanuel Kibrom
JWJana Winkler
Jana Winkler
KLKatherine Leon
Katherine Leon
HSHannah Stoveken
Hannah Stoveken
DADemet Araç
Demet Araç
Adhesion G-protein-coupled receptors (aGPCRs) play critical roles in diverse cellular processes in neurobiology, development, immunity, and numerous diseases. The lack of molecular understanding of their activation mechanisms, especially with regard to the transmembrane domains, hampers further studies to facilitate aGPCR-targeted drug development. Latrophilin-1/ADGRL1 is a model aGPCR that regulates synapse formation and embryogenesis, and its mutations are associated with cancer and attention-deficit/hyperactivity disorder. Here, we established functional assays to monitor latrophilin-1 function and showed the activation of latrophilin-1 by its endogenous agonist peptide. Via a comprehensive mutagenesis screen, we identified transmembrane domain residues essential for latrophilin-1 basal activity and for agonist peptide response. Strikingly, a cancer-associated mutation exhibited increased basal activity and failed to rescue the embryonic developmental phenotype in transgenic worms. These results provide a mechanistic foundation for future aGPCR-targeted drug design.

19 March 2026 in Blood
Verified
Journal Article
Closed access
GSGabriel S. Salzman
Gabriel S. Salzman
AMAnn Mullally
Ann Mullally
The discovery of calreticulin (CALR) mutations in patients with myeloproliferative neoplasms (MPNs) has paved the way for the elucidation of a unique disease mechanism that is particularly well suited to targeting by biologics. All MPN-associated pathogenic CALR mutations are characterized by a frameshift, resulting in translation of the same neoantigen peptide. This neoantigen directly activates the thrombopoietin receptor, leading to uncontrolled neoplastic cell proliferation. Current therapeutic approaches for MPNs are focused primarily on blood count control. Furthermore, current approaches are neither disease modifying nor clonally selective. However, because the mutant CALR neoantigen peptide is functional and not expressed in normal physiology, it is an ideal drug target. Here, we review the structure and function of mutant CALR, including the subtle yet clinically and therapeutically relevant differences between the 2 most commonly occurring types of mutation. We also review the current therapeutic landscape for CALR-mutated MPNs, highlighting the areas in which current approaches are inadequate. Finally, we review ongoing clinical and preclinical experimental approaches for targeting mutant CALR in MPNs in a clonally selective manner using monoclonal antibodies, bispecific antibodies, cancer vaccination, chimeric antigen receptor T cells, and antibody-drug conjugates. Taken together, we expect that ongoing developments in mutant CALR–targeted therapeutics will lead to promising novel strategies for long-term disease control.